RepG3

RepG3 is a third-generation synthetic peptide developed by Newal R&D, designed to mimic the Alpha domain of human ezrin. Its primary mechanism of action involves the modulation of the TLR4-RAGE loop and associated membrane-associated multi-receptor-to-cell protein-signalling complexes. By targeting these pathways, RepG3 aims to regulate aberrant immune responses and signaling associated with chronic inflammatory and infectious conditions. The drug is currently being explored for a variety of indications, including Long COVID, COVID vaccine injury, and several sexually transmitted infections (STIs) such as chlamydia, HPV, and syphilis, as well as fungal infections like candidiasis.

Other names

Generation-3 synthetic peptideGeneration3 synthetic peptideGeneration 3 synthetic peptideezrin-mimetic peptide